Startup profile · funding coverage
Inceptive
AI biotech designing mRNA molecules for vaccines and therapeutics — founded by Transformer co-author Jakob Uszkoreit.
Stage
series a
Status
private
Coverage
full
Why Inceptive is interesting
Valuation tripped to $300M+ on biological-software thesis; licenses designed molecules to pharma partners.
Key facts
- Series A (Sep 2023): $100M with a16z and NVentures; Obvious Ventures, S32, ARTIS also named (Endpoints News)
- Co-investors not in VCT directory: NVentures, Obvious Ventures, S32, ARTIS
- VCT directory co-investors: none mapped (non-directory syndicates noted above); reviewed 2026-07-24
Investors in our directory
Funds linked from Inceptive's profile — open a fund page for stage focus and related deal articles.
Industries
Generalist Technology
Industry hub pages are rolling out from our fund-derived baseline taxonomy.
Related funding articles
Venture Capital Tracker pieces that cover Inceptive's financing or category context.
Last updated: 2026-07-24